At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease: New York Saturday, April 19, 2025, 10:00 Hrs [ ...

US flu activity declined steadily again last week, with rates of influenza-like illness (ILI) dropping further and staying ...

The rest of the 23 CWD-positive deer harvested by hunters during the 2024-25 hunting season were found in Allen, Hardin, ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.